Global Age-related Macular Degeneration Market Introduction and Overview
According to SPER Market Research, the Global Age-related Macular Degeneration Market is estimated to reach USD 26.34 billion by 2033 with a CAGR of 10.97%.
The report includes an in-depth analysis of the Global Age-related Macular Degeneration Market, including market size and trends, product mix, applications, and supplier analysis. Age-related macular degeneration (AMD), also referred to as macular degeneration, is a condition in which the macula of the retina thins, leading to a loss of central vision. People over 60 may experience irreversible vision loss as a result of age-related macular degeneration, which is more prevalent in the older population. There are two types of age-related macular degeneration (wet AMD): dry Macular Degeneration (Dry AMD) and wet AMD. The most common type of macular degeneration is dry age-related macular degeneration, which causes central vision loss when the macula thins with age.
- The US Food and Drug Administration (FDA) approved F. Hoffmann-La Roche Ltd.'s Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) in 2024 for the treatment of patients with nAMD. These prefilled syringes provide a convenient way to take drugs.
- Iveric Bio is a clinical-phase biotechnology business that creates novel treatments for retinal illnesses. In 2023, Astellas Pharma Inc. (Japan) purchased Iveric Bio. With this purchase, Astella adds the ophthalmologic medication Izervay to its portfolio of pharmaceutical products.
Market Opportunities and Challenges
Opportunities- Monoclonal antibodies and recombinant fusion proteins are currently the only medications being developed to treat AMD, and because they require frequent dosing, they are typically costly. A high rate of treatment discontinuation is typically a result of the patients' increasing treatment burden brought on by the high expense of care. To combat patient non-adherence to treatment, companies in the AMD medicine industry are investigating novel drug modalities such gene therapy, hydrogels, and inhibitor pharmaceuticals (oral dosage). To treat wet AMD, for example, businesses such as Adverum Biotechnologies, Inc. (US) are creating gene treatments. Furthermore, As the world's population continues to increase and the demographics show that the majority of individuals are older, the prevalence of AMD is increasing at a rate never seen before. As to the National Eye Institute, AMD is the main reason why older people lose their vision. Moreover, the illness is more likely to affect people over 60 years old.
Challenges- As the world's population continues to increase and the demographics show that the majority of individuals are older, the prevalence of AMD is increasing at a rate never seen before. As to the National Eye Institute, AMD is the main reason why older people lose their vision. Moreover, the illness is more likely to affect people over 60 years old. With the aging of the global population, AMD is expected to become more prevalent, with a higher frequency in Western nations. There are currently about 1.1 billion tobacco smokers worldwide, and if current trends continue, that number is expected to treble by 2050, according to the Globe Health Organization. Furthermore, patients' access to novel therapies may be restricted by their high cost, particularly in low- and middle-income nations. The launch of novel therapies may be delayed by regulatory obstacles and regionally specific approval procedures, which would further complicate market dynamics. Additionally, there is a dearth of knowledge and instruction regarding AMD, which may cause therapy and diagnosis to be delayed.
Market Competitive Landscape
The Global Age-related Macular Degeneration Market is highly consolidated. Some of the market key players are Amgen Inc., Bausch Health Companies Inc., Bayer AG, Biogen, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis, Others.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Product, By Molecules, By Type of AMD, By Approval Type, By End User |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Amgen Inc., Bausch Health Companies Inc., Bayer AG, Biogen, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis, Others. |
COVID-19 Impact on Global Age-related Macular Degeneration Market
The global market for age-related macular degeneration (AMD) was greatly impacted by the COVID-19 pandemic in a number of ways. Patients missed important consultations and follow-up care as a result of delays in routine eye exams and treatments brought on by disruptions in healthcare services. Chronic diseases like AMD were frequently overlooked in favor of COVID-19, which led to a decline in detection rates and an increase in symptoms for many individuals. Further complicating patient management were supply chain disruptions that impacted the availability of necessary pharmaceuticals and diagnostic equipment. Positively, some patients were able to receive consultations remotely because the pandemic hastened the implementation of telehealth services. As healthcare systems continue to adjust and recover from the disruptions caused by the epidemic, the long-term impacts on patient outcomes and the market as a whole continue to be a worry.
Key Target Audience:
- Ophthalmologists
- Optometrists
- Patients with AMD
- Caregivers
- Healthcare Institutions
- Pharmaceutical Companies
- Medical Device Manufacturers
- Payers and Insurance Providers
- Researchers and Academics
Our in-depth analysis of the Global Age-related Macular Degeneration Market includes the following segments:
| By Products: | LucentisEylea & Eylea HDVabysmoSofovreOthers |
| By Molecules: | RanibizumabAfliberceptFaricimabPegcetoplanOthers |
| By Type of AMD: | Wet AMDDry AMD |
| By Approval Type: | BiologicBiosimilar |
| By End User: | HospitalsSpecialty CentersLong-Term Care Facilities |
Key Topics Covered in the Report:
- Global Age-related Macular Degeneration Market Size (FY’2024-FY’2033)
- Overview of Global Age-related Macular Degeneration Market
- Segmentation of Global Age-related Macular Degeneration Market By Products (Lucentis, Eylea & Eylea HD, Vabysmo, Sofovre, Others)
- Segmentation of Global Age-related Macular Degeneration Market By Molecules Technology (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Others)
- Segmentation of Global Age-related Macular Degeneration Market By Type of AMD (Wet AMD, Dry AMD)
- Segmentation of Global Age-related Macular Degeneration Market By Approval Type (Biologic, Biosimilar)
- Segmentation of Global Age-related Macular Degeneration Market By End User (Hospitals, Specialty Centers, Long-Term Care Facilities)
- Statistical Snap of Global Age-related Macular Degeneration Market
- Expansion Analysis of Global Age-related Macular Degeneration Market
- Problems and Obstacles in Global Age-related Macular Degeneration Market
- Competitive Landscape in the Global Age-related Macular Degeneration Market
- Impact of COVID-19 and Demonetization on Global Age-related Macular Degeneration Market
- Details on Current Investment in Global Age-related Macular Degeneration Market
- Competitive Analysis of Global Age-related Macular Degeneration Market
- Prominent Players in the Global Age-related Macular Degeneration Market
- SWOT Analysis of Global Age-related Macular Degeneration Market
- Global Age-related Macular Degeneration Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Age-related Macular Degeneration Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Age-related Macular Degeneration Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Age-related Macular Degeneration Market
7. Global Age-related Macular Degeneration Market, By Products (USD Million) 2020-2033
7.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Products, 2020-2026
7.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Products, 2027-2033
7.3. Lucentis
7.4. Eylea & Eylea HD
7.5. Vabysmo
7.6. Sofovre
7.7. Others
8. Global Age-related Macular Degeneration Market, By Molecules (USD Million) 2020-2033
8.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Molecules, 2020-2026
8.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Molecules, 2027-2033
8.3. Ranibizumab
8.4. Aflibercept
8.5. Faricimab
8.6. Pegcetoplan
8.7. Others
9. Global Age-related Macular Degeneration Market, By Type of AMD (USD Million) 2020-2033
9.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Type of AMD, 2020-2026
9.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Type of AMD, 2027-2033
9.3. Wet AMD
9.4. Dry AMD
10. Global Age-related Macular Degeneration Market, By Approval Type (USD Million) 2020-2033
10.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Approval Type, 2020-2026
10.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By Approval Type, 2027-2033
10.3. Biologic
10.4. Biosimilar
11. Global Age-related Macular Degeneration Market, By End User (USD Million) 2020-2033
11.1. Global Age-related Macular Degeneration Market Size, Share and Forecast, By End User, 2020-2026
11.2. Global Age-related Macular Degeneration Market Size, Share and Forecast, By End User, 2027-2033
11.3. Hospitals
11.4. Specialty Centers
11.5. Long-Term Care Facilities
12. Global Age-related Macular Degeneration Market Forecast, 2020-2033 (USD Million)
12.1. Global Age-related Macular Degeneration Market Size and Market Share
13. Global Age-related Macular Degeneration Market, By Region, 2020-2033 (USD Million)
13.1. Global Age-related Macular Degeneration Market Size and Market Share By Region (2020-2026)
13.2. Global Age-related Macular Degeneration Market Size and Market Share By Region (2027-2033)
13.3. Asia-Pacific
13.3.1. Australia
13.3.2. China
13.3.3. India
13.3.4. Japan
13.3.5. South Korea
13.3.6. Rest of Asia-Pacific
13.4. Europe
13.4.1. France
13.4.2. Germany
13.4.3. Italy
13.4.4. Spain
13.4.5. United Kingdom
13.4.6. Rest of Europe
13.5. Middle East and Africa
13.5.1. Kingdom of Saudi Arabia
13.5.2. United Arab Emirates
13.5.3. Qatar
13.5.4. South Africa
13.5.5. Egypt
13.5.6. Morocco
13.5.7. Nigeria
13.5.8. Rest of Middle-East and Africa
13.6. North America
13.6.1. Canada
13.6.2. Mexico
13.6.3. United States
13.7. Latin America
13.7.1. Argentina
13.7.2. Brazil
13.7.3. Rest of Latin America
14. Company Profile
14.1. Amgen Inc.
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. Bausch Health Companies Inc.
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. Bayer AG
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. Biogen
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. F. Hoffmann-La Roche Ltd
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. Novartis AG
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. Pfizer Inc.
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Regeneron Pharmaceuticals Inc.
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. Samsung Bioepis
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
